Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study.
Pedro Mercader GarcìaMaria-Antonia Pastor-NietoRicardo Gonzalez-PerezSusana Cordoba-GuijarroGimenez-Arnau Ana MariaInmaculada Ruiz-GonzalezVeronica Mora-FernandezJavier MiquelJuan Francisco Silvestre SalvadorFrancisco Javier Ortiz-FrutosTatiana Sanz-SánchezMercedes Rodríguez SernaPatricia Pérez FealJavier Sánchez PérezFelipe Heras-MendazaEsther Serra BaldrichVioleta Zaragoza-NinetMarcos Hervella-GarcesMaria-Elena Gatica-OrtegaIgnacio García DovalMiguel Ángel Gallego DescalzoLeopoldo Borregonull nullPublished in: Contact dermatitis (2021)
Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.